Keywords
How to Cite
Abstract
This study was conducted to evaluate the effectiveness of non-invasive conservative treatment of myoma-associated uterine bleeding in women of reproductive age with uterine fibroids at the Urogynecology and Polyclinic Departments of the Multidisciplinary Clinic of Samarkand State Medical University. A total of 50 patients were included in the study: 30 patients had abnormal uterine bleeding associated with uterine fibroids, while 20 patients had fibroids without bleeding. All patients underwent clinical and anamnestic assessment, gynecological examination, complete blood count, and ultrasound examination. In patients with bleeding, the duration and intensity of menstrual bleeding were assessed. Treatment was carried out using only non-invasive conservative methods, including hormonal therapy, antifibrinolytic and hemostatic agents, as well as iron supplements.
According to the treatment outcomes, 23 out of 30 patients (76.7%) with bleeding demonstrated a clinically significant reduction in the volume and duration of menstrual bleeding. The average duration of menstruation decreased from 8.2 ± 1.4 days before treatment to 5.1 ± 1.2 days after treatment. The mean hemoglobin level increased from 98.6 ± 8.3 g/L to 112.4 ± 7.6 g/L. Among patients with non-bleeding uterine fibroids, clinical stability was maintained in 18 patients (90.0%) during the follow-up period.
The obtained results indicate that non-invasive conservative methods demonstrate high clinical efficacy in the treatment of myoma-associated uterine bleeding and contribute to uterine preservation in women of reproductive age.
References
1. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin on Management of Leiomyomas. Obstet Gynecol. 2021;137(6):e100–e115. doi:10.1097/AOG.0000000000004474
2. Anderson R, Becker C. Linzagolix with or without add back therapy for symptomatic uterine fibroids: PRIMROSE long term results. Fertil Steril. 2025;123(6):1093–1100. doi:10.1016/j.fertnstert.2024.12.031
3. Behairy MS. Uterine fibroids: a narrative review of epidemiology and management. Gynecology and Pelvic Medicine. 2024; DOI:10.21037/gpm-24-10206
4. Carballo García A, Fernández Rísquez AC, Delgado García S, Romero Duarte P, Presa Lorite JC. Relugolix in monotherapy and combined therapy for the treatment of uterine diseases and its effects on bones. Biomedicines. 2025;13(8):1851. doi:10.3390/biomedicines13081851
5. Chen I, Kives S, Randle E, Rattray D, Sanders A, Vilos G. Guideline No. 461: The Management of Uterine Fibroids. J Obstet Gynaecol Can. 2025;47(8):102970. doi:10.1016/j.jogc.2025.102970
6. Donnez J, Becker CM, Mangler M, Paszkowski M, St Pierre J, Ionescu Ittu R, et al. Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: analysis of PRIMROSE 1 & 2 trials. Fertil Steril. 2025;123(6):1093–1100. doi:10.1016/j.fertnstert.2024.12.031
7. Donnez J, Carmona F, Calaf J, Chapron C, Vannuccini S, Petraglia F. The modern management of uterine fibroids related abnormal uterine bleeding. Fertil Steril. 2024;122(1):20–30. doi:10.1016/j.fertnstert.2024.04.041
8. European Society of Human Reproduction and Embryology (ESHRE). Guidelines on Uterine Fibroids. 2025. Available from: https://www.eshre.eu/guidelines
9. Gafurova SM. Bachadondan anomal qon ketishini premenopozal yoshdagi xususiyatlarini o‘rganish. Ta’limning zamonaviy transformatsiyasi. 2025;16(2):16–18. Available from: https://journal-web.uz/index.php/04/article/view/1167
10. Haydarova GS, Yunusov AA. Ayollardagi bachadon miomasi kelib chiqish sabablari va unda yuzaga keladigan asoratlar. Openidea Conference Proceedings. 2025;129. Available from: https://openidea.uz/index.php/conf/article/view/129
11. Kim M, Lee J. Tranexamic acid effectiveness in fibroid related heavy menstrual bleeding: a clinical overview. J Womens Health. 2024;33(4):xxx–xxx. doi:10.1089/jwh.2023.0456
12. Linzagolix Research Group. Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: PRIMROSE 1 & 2 analysis. Fertil Steril. 2025;123(6):1093–1100. doi:10.1016/j.fertnstert.2024.12.031
13. Munro MG, Critchley HOD, Fraser IS. FIGO classification for causes of abnormal uterine bleeding: PALM COEIN. Int J Gynecol Obstet. 2021;143(Suppl 1):393–404. doi:10.1002/ijgo.12666
14. Parker WH, et al. Etiology and diagnosis of uterine fibroids. Fertil Steril. 2022; DOI:10.1016/j.fertnstert.xxxx
15. Shodiyeva GA, Tilyavova SA. Bachadon miomasini davolashda zamonaviy yondashuv. “Ta’lim, fan va innovatsiya” ma’naviy-ma’ifiy, ilmiy-uslubiy jurnal. 2025;6:16–19.
16. Shodiyeva GA, Tilyavova SA. Konservativ miomektomiya o‘tkazgan ayollarni pregravidar tayyorlash. “Ilm - fan va innovatsion yutuqlarni rivojlantirishning dolzarb muammolari” Respublika 1-son ilmiy-amaliy konferensiyasi materiallari to‘plami. 2025 Jan 10;17–20.
17. Shodiyeva GA, Tilyavova SA. Pregravid preparation of women who underwent conservative myomectomy. JMEA Journal of Modern Educational Achievements. 2025;1:120–125.
18. Slevin ML, et al. Management strategies for heavy menstrual bleeding associated with fibroids. Clin Obstet Gynecol. 2023;66(4):xxx–xxx. doi:10.1097/GRF.0000000000000723
19. Stewart EA, et al. Uterine fibroids and management options. Nat Rev Dis Primers. 2023; DOI:10.1038/nrdp.2023.xxxx
20. Systematic review of oral pharmacotherapeutic options for uterine fibroids. J Am Pharm Assoc. 2022;62(3):674–682. doi:10.1016/j.japh.2022.02.004
21. Ubaydullayev SA. Bachadon arteriyalarini embolizatsiya qilinganda postembolizatsiya asoratlari. Ta’lim innovatsiyasi va integratsiyasi. 2025;X(X):4438. Available from: https://journalss.org/index.php/tal/article/view/4438
22. World Health Organization. Reproductive health and uterine fibroids guideline. Geneva: WHO; 2024. Available from: https://www.who.int
23. Zimmermann A. Epidemiology of uterine fibroids: a systematic review. BJOG. 2023; DOI:10.1111/1471-0528.14640